Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Teva Pharmaceutical Industries (TEVJF) over the last 11 years, with Q4 2025 value amounting to $739.0 million.

  • Teva Pharmaceutical Industries' Accumulated Expenses rose 1842.95% to $739.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $739.0 million, marking a year-over-year increase of 1842.95%. This contributed to the annual value of $739.0 million for FY2025, which is 1842.95% up from last year.
  • Teva Pharmaceutical Industries' Accumulated Expenses amounted to $739.0 million in Q4 2025, which was up 1842.95% from $561.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Accumulated Expenses' 5-year high stood at $739.0 million during Q4 2025, with a 5-year trough of $432.0 million in Q1 2023.
  • In the last 5 years, Teva Pharmaceutical Industries' Accumulated Expenses had a median value of $518.5 million in 2021 and averaged $533.6 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Accumulated Expenses plummeted by 1781.02% in 2021, and later skyrocketed by 1842.95% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Accumulated Expenses (Quarter) stood at $563.0 million in 2021, then increased by 0.53% to $566.0 million in 2022, then grew by 7.95% to $611.0 million in 2023, then increased by 2.13% to $624.0 million in 2024, then grew by 18.43% to $739.0 million in 2025.
  • Its Accumulated Expenses was $739.0 million in Q4 2025, compared to $561.0 million in Q3 2025 and $481.0 million in Q2 2025.